Justyna Rybka

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Andrew H. Wei, Hartmut Döhner, Christopher Pocock et al. · New England Journal of Medicine · 2020 · 403 citations · Full text

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, Hartmut Döhner, Christopher Pocock et al. · Blood · 2019 · 97 citations

The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study

Claudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi et al. · The Lancet Haematology · 2016 · 74 citations

Positron Emission Tomography, Interim Pet Scan, Prognostic Biomarkers +11

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak et al. · The Lancet Oncology · 2023 · 69 citations · Full text

Hematological Malignancy, Interim Analysis, Oncology +10

Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway.

Krystyna Dąbrowska, Adam Opolski, Joanna Wietrzyk et al. · PubMed · 2004 · 65 citations

Antitumor Activity, Immunology, Bacteriophage +19